PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Trospium chloride - Overactive bladder (adults)
PAD Profile : Trospium chloride - Overactive bladder (adults)
Keywords :
antimuscarinics, OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, urinary urgency, anticholinergics
Brand Names Include :
Regurin, Regurin XL
Traffic Light Status
Status 1 of 2.
Status :
Green (see narrative)
Important
Formulations :
- Immediate release tablets
Important Information :
Alternative 1st line in patients where anticholinergic burden is a problem or on medicines that interact.
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Status :
Green (see narrative)
Important
Formulations :
- Modified release tablets
Important Information :
2nd line in patients where anticholinergic burden is a problem or on medicines that interact.
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Fesoterodine fumarate
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.
05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Solifenacin is the 1st line treatment option.
Trospium immediate release or modified release are recommended as suitable treatment options where solifenacin is not suitable.
See Selection Tool for locally agreed OAB treatment options
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence